Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.
Emine DuranZeynep Ozge OzturkAbdulsamet ErdenYahya BuyukasikOmer DizdarGözde Kübra YardimciBayram FarisoğullarıZehra ÖzsoyGizem AyanGüllü Sandal UzunMustafa EkiciErdinc UnaldiLevent KilicAli AkdoğanÖmer KaradağŞaziye Şule Apraş BilgenSedat KirazUmut KalyoncuAli Ihsan ErtenliPublished in: Rheumatology and therapy (2023)
The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.